|
1
|
Das V, Kalita J and Pal M: Predictive and
prognostic biomarkers in colorectal cancer: A systematic review of
recent advances and challenges. Biomed Pharmacother. 87:8–19. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Pabla B, Bissonnette M and Konda VJ: Colon
cancer and the epidermal growth factor receptor: Current treatment
paradigms, the importance of diet and the role of chemoprevention.
World J Clin Oncol. 6:133–141. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Shekhar MP: Drug resistance: Challenges to
effective therapy. Curr Cancer Drug Targets. 11:613–623. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Kimura M, Endo H, Inoue T, Nishino K,
Uchida J, Kumagai T, Kukita Y, Kato K, Imamura F and Inoue M:
Analysis of ERBB ligand-induced resistance mechanism to crizotinib
by primary culture of lung adenocarcinoma with EML4-ALK fusion
gene. J Thorac Oncol. 10:527–530. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Zhang L, Ngo JA, Wetzel MD and Marchetti
D: Heparanase mediates a novel mechanism in lapatinib-resistant
brain metastatic breast cancer. Neoplasia. 17:101–113. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Borges S, Döppler HR and Storz P: A
combination treatment with DNA methyltransferase inhibitors and
suramin decreases invasiveness of breast cancer cells. Breast
Cancer Res Treat. 144:79–91. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Ma J, Fang B, Zeng F, Ma C, Pang H, Cheng
L, Shi Y, Wang H, Yin B, Xia J, et al: Down-regulation of miR-223
reverses epithelial-mesenchymal transition in gemcitabine-resistant
pancreatic cancer cells. Oncotarget. 6:1740–1749. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Camplejohn RS: A critical review of the
use of vincristine (VCR) as a tumour cell synchronizing agent in
cancer therapy. Cell Tissue Kinet. 13:327–335. 1980.PubMed/NCBI
|
|
9
|
Antoniou A, Pharoah PD, Narod S, Risch HA,
Eyfjord JE, Hopper JL, Loman N, Olsson H, Johannsson O, Borg A, et
al: Average risks of breast and ovarian cancer associated with
BRCA1 or BRCA2 mutations detected in case Series unselected for
family history: A combined analysis of 22 studies. Am J Hum Genet.
72:1117–1130. 2003. View
Article : Google Scholar : PubMed/NCBI
|
|
10
|
Singh KK, Shukla PC, Quan A, Al-Omran M,
Lovren F, Pan Y, Brezden-Masley C, Ingram AJ, Stanford WL, Teoh H
and Verma S: BRCA1 is a novel target to improve endothelial
dysfunction and retard atherosclerosis. J Thorac Cardiovasc Surg.
146:949–960. e4. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Phelan CM, Iqbal J, Lynch HT, Lubinski J,
Gronwald J, Moller P, Ghadirian P, Foulkes WD, Armel S, Eisen A, et
al: Incidence of colorectal cancer in BRCA1 and BRCA2 mutation
carriers: Results from a follow-up study. Br J Cancer. 110:530–534.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Wang TY, Zhang QQ, Zhang X, Sun QL, Zhao
CP and Wang XY: The effect of recombinant lentiviral vector
encoding miR-145 on human esophageal cancer cells. Tumour Biol.
36:9733–9738. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Zhang JH, Du AL, Wang L, Wang XY, Gao JH
and Wang TY: Episomal lentiviral vector-mediated miR-145
overexpression inhibits proliferation and induces apoptosis of
human esophageal carcinomas cells. Recent Pat Anticancer Drug
Discov. 11:453–460. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Dong WH, Wang TY, Wang F and Zhang JH:
Simple, time-saving dye staining of proteins for sodium dodecyl
sulfate-polyacrylamide gel electrophoresis using Coomassie blue.
PLoS One. 6:e223942011. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Chao MW, Lai MJ, Liou JP, Chang YL, Wang
JC, Pan SL and Teng CM: The synergic effect of vincristine and
vorinostat in leukemia in vitro and in vivo. J Hematol Oncol.
8:822015. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Jung SO, Kim SY, Kim JO, Jung SS, Park HS,
Moon JY, Kim SM and Lee JE: Promising effects of 3rd line
cyclophosphamide, adriamycin and vincristine (CAV) and 4th line
ifosfamide and carboplatin chemotherapy in refractory small cell
lung cancer. Thorac Cancer. 6:659–663. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Xu Y and Qiu L: Nonspecifically enhanced
therapeutic effects of vincristine on multidrug-resistant cancers
when coencapsulated with quinine in liposomes. Int J Nanomedicine.
10:4225–4237. 2015.PubMed/NCBI
|
|
18
|
Qiu JG, Zhang YJ, Li Y, Zhao JM, Zhang WJ,
Jiang QW, Mei XL, Xue YQ, Qin WM, Yang Y, et al: Trametinib
modulates cancer multidrug resistance by targeting ABCB1
transporter. Oncotarget. 6:15494–15509. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Tsubaki M, Takeda T, Ogawa N, Sakamoto K,
Shimaoka H, Fujita A, Itoh T, Imano M, Ishizaka T, Satou T and
Nishida S: Overexpression of survivin via activation of ERK1/2,
Akt, and NF-κB plays a central role invincristine resistance in
multiple myeloma cells. Leuk Res. 39:445–452. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Bartram I, Erben U, Ortiz-Tanchez J,
Blunert K, Schlee C, Neumann M, Heesch S and Baldus CD: Inhibition
of IGF1-R overcomes IGFBP7-induced chemotherapy resistance in
T-ALL. BMC Cancer. 15:6632015. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Tivnan A, Zakaria Z, O'Leary C, Kögel D,
Pokorny JL, Sarkaria JN and Prehn JH: Inhibition of multidrug
resistance protein 1 (MRP1) improves chemotherapy drug response in
primary and recurrent glioblastoma multiforme. Front Neurosci.
9:2182015. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Sun QL, Zhao CP, Wang TY, Hao XB, Wang XY,
Zhang X and Li YC: Expression profile analysis of long non-coding
RNA associated with vincristine resistance in colon cancer cells by
next-generation sequencing. Gene. 572:79–86. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Elia AE and Elledge SJ: BRCA1 as tumor
suppressor: Lord without its RING? Breast Cancer Res. 14:3062012.
View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Lohse I, Borgida A, Cao P, Cheung M,
Pintilie M, Bianco T, Holter S, Ibrahimov E, Kumareswaran R,
Bristow RG, et al: BRCA1 and BRCA2 mutations sensitize to
chemotherapy in patient-derived pancreatic cancer xenografts. Br J
Cancer. 113:425–432. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Dumontet C, Jaffrezou JP, Tsuchiya E,
Duran GE, Chen G, Derry WB, Wilson L, Jordan MA and Sikic BI:
Resistance to microtubule-targeted cytotoxins in a K562 leukemia
cell variant associated with altered tubulin expression and
polymerization. Bull Cancer. 91:E81–E112. 2004.PubMed/NCBI
|
|
26
|
Cousein E, Barthélémy C, Poullain S, Simon
N, Lestavel S, Williame V, Joiris E, Danel C, Clavey V, Brossard D,
et al: P-glycoprotein and cytochrome P450 3A4 involvement in
risperidone transport using an in vitro Caco-2/TC7 model and an in
vivo model. Prog Neuropsychopharmacol Biol Psychiatry. 31:878–886.
2007. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Liu CL, Lim YP and Hu ML: Fucoxanthin
attenuates rifampin-induced cytochrome P450 3A4 (CYP3A4) and
multiple drug resistance 1 (MDR1) gene expression through pregnane
X receptor (PXR)-mediated pathways in human hepatoma HepG2 and
colon adenocarcinoma LS174T cells. Mar Drugs. 10:242–257. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Yu CJ, Ou JH, Wang ML, Jialielihan N and
Liu YH: Elevated survivin mediated multidrug resistance and reduced
apoptosis in breast cancer stemcells. J BUON. 20:1287–1294.
2015.PubMed/NCBI
|
